ALBANY (NBC-WNYT) – Dr. Brian P. Murray of Albany Memorial Hospital discusses his low-tech approach to treating overactive bladder using the LABORIE Urostym® Biofeedback System.
The LABORIE Urostym® provides practices with a non-surgical approach to treating Urinary and Fecal Incontinence. The Urostym® system provides the most current protocols for pelvic floor conservative treatment and generates reports quickly and easily that include complete information for analysis, treatment and results.
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).
LABORIE Medical Technologies (“LABORIE”) announced the successful completion of the tender offer by its affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”) to purchase all outstanding shares of common stock of Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”)
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Cogentix Medical Inc., (NASDAQ: CGNT)